Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Cash from Operations (2019 - 2025)

Revolution Medicines has reported Cash from Operations over the past 7 years, most recently at 274238000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 274238000.0 for Q4 2025, down 98.31% from a year ago — trailing twelve months through Dec 2025 was 897741000.0 (down 61.05% YoY), and the annual figure for FY2025 was 897741000.0, down 61.05%.
  • Cash from Operations for Q4 2025 was 274238000.0 at Revolution Medicines, down from 207311000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for RVMD hit a ceiling of 34081000.0 in Q2 2021 and a floor of 274238000.0 in Q4 2025.
  • Median Cash from Operations over the past 5 years was 83809000.0 (2023), compared with a mean of 108866500.0.
  • Biggest five-year swings in Cash from Operations: decreased 13.11% in 2023 and later crashed 157.34% in 2024.
  • Revolution Medicines' Cash from Operations stood at 39265000.0 in 2021, then crashed by 57.36% to 61788000.0 in 2022, then crashed by 95.12% to 120563000.0 in 2023, then fell by 14.7% to 138290000.0 in 2024, then crashed by 98.31% to 274238000.0 in 2025.
  • The last three reported values for Cash from Operations were 274238000.0 (Q4 2025), 207311000.0 (Q3 2025), and 221757000.0 (Q2 2025) per Business Quant data.